Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson's disease patients: an European multicentre survey

Keyphrases

• Tolerability 100%
• Transdermal 100%
• Parkinson Patients 100%
• Dopamine Agonist 100%
• Ergot 100%
• Older Patients 80%
• Young Patients 40%
• Dopamine Agonist Therapy 40%
• No Significant Difference 20%
• Old Age 20%
• Medical Records 20%
• Clinical Interview 20%
• Potential Gains 20%
• Disease Duration 20%
• European Centre 20%
• Agonist Treatment 20%
• Routine Care 20%
• Patients with Parkinson's Disease 20%
• Non-demented 20%
• Follow-up Survey 20%
• Daily Dose 20%
• Extended Release 20%
• Interview-based 20%
• Retrospective Data 20%
• Skin Patch 20%
• Patient Survey 20%
• Real-life Setting 20%
• Real-life Data 20%
• Transdermal Drugs 20%
• Rotigotine 20%
• Ropinirole 20%
• Prolonged Release 20%
• Pramipexole 20%
• Data Capture 20%
• Long-acting Therapy 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Parkinson's Disease 100%
• Transdermal 100%
• Dopamine Receptor Stimulating Agent 100%
• Disease 14%
• Rotigotine 14%
• Transdermal Patch 14%
• Pramipexole 14%
• Ropinirole 14%